Economy

Aimmune Therapeutics, Inc. (AIMT) Hits New 1-Year High on Analyst Upgrade

Several research analysts have recently issued reports on AIMT shares. With that said, researchers took a deep dive into the hotly debated question: is it too late to buy Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc. (AIMT) shares are up 27.18% for the week and that has got investors and traders sitting up and taking note. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a "buy" rating in a report on Thursday, July 27th.

Among 4 analysts covering Corcept Therapeutics (NASDAQ:CORT), 4 have Buy rating, 0 Sell and 0 Hold. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Aimmune Therapeutics presently has an average rating of "Hold" and an average target price of $51.00.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT)'s stock has performed at 25.48%. Following the transaction, the insider now directly owns 25,000 shares in the company, valued at $420,000. These analysts have also projected a Low Estimate of $-0.76/share and a High Estimate of $-0.69/share. Aimmune Therapeutics, Inc. The company's market capitalization is $1.66 billion. AIMT's latest closing price was 58.70% away from the average price of 200 days while it maintained a distance of 42.95% from the 50 Day Moving Average and 29.61% away compared to its SMA 20.

Analysts expect Aimmune Therapeutics Inc (NASDAQ:AIMT) to report $-0.72 EPS on November, 13.They anticipate $0.19 EPS change or 35.85 % from last quarter's $-0.53 EPS.

As of the last earnings report the EPS was $-2.25 and is estimated to be $-2.71 for the current year with 50,535,000 shares outstanding.

What Historical Figures Say About Aimmune Therapeutics, Inc. The company was initiated on Monday, August 31 by Credit Suisse.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. President and CEO Stephen George Dilly sold 98,846 shares at a price of $26.26 on Friday the 6th.

About 2.72M shares traded or 649.83% up from the average. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The stock is also considered overbought with an RSI (14) now at 86.18. The shares were purchased at an average price of $26.24. Following the completion of the transaction, the insider now owns 20,000 shares of the company's stock, valued at $500,000. The disclosure for this sale can be found here. The company trades on average around 27024000 shares per market session. Corporate insiders own 24.56% of the company's stock. After $0.10 actual earnings per share reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 40.00% EPS growth. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company's stock valued at $1,892,000 after purchasing an additional 4,788 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Aimmune Therapeutics during the third quarter valued at $133,000. State Street Corp now owns 1,087,320 shares of the biotechnology company's stock worth $22,351,000 after purchasing an additional 228,429 shares in the last quarter.

As of quarter end Point72 Asset Management, L.p. had bought 314,259 shares growing its stake by 46.1%. Eagle Asset Management Inc. lifted its position in shares of Aimmune Therapeutics by 6.3% in the 2nd quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company's stock worth $4,675,000 after purchasing an additional 132,603 shares during the period.

Aimmune Therapeutics, Inc.is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system created to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.



Like this

Latest


25 October 2017
Storm damages reported in North Carolina storm
Authorities in Watauga and McDowell counties reported completing water rescues as heavy rains caused flash floods in some areas. In South Carolina, tractor trailers were flipped, homes damaged and trees downed by a possible tornado in the Spartanburg area.

25 October 2017
Trump rejects caps on 401(k) plans as part of GOP tax plan
Rand Paul, who hails from McConnell's state of Kentucky and voted against the bill because he said it did not cut spending enough. This year's measure calls for $473 billion in cuts from Medicare over 10 years and more than $1 trillion from Medicaid.

25 October 2017
Analysts Review: Precision Drilling Corp (PDS)
Analysts are also projecting an Average Revenue Estimate for Precision Drilling Corporation as $261900 in the Current Quarter. Dimensional Fund Advisors LP grew its stake in shares of Precision Drilling Corporation by 0.4% during the first quarter.

25 October 2017
Offaly areas need improvements to water treatment processes
A number of Offaly area have been named on an EPA report as requiring improvements in their water treatment and supply network. These 50 areas account for nearly two thirds of the national waste water load collected in all large urban areas.

25 October 2017
Pa. unemployment rate ticks down
The Mahoning Valley's nonseasonally adjusted unemployment rate was 7.2 percent during September, up 1 percent from last September. In May, Linn County's unemployment dipped to 4.1 percent, the lowest mark since OR began tracking county-by-county data in 1990.

25 October 2017
Boston Scientific Corporation (NYSE:BSX) has industry P/E ratio of 12.47
Continental Advisors Llc increased Wells Fargo Co New (NYSE:WFC) stake by 67,116 shares to 123,716 valued at $6.86M in 2017Q2. The stock of Boston Scientific Corporation (NYSE: BSX ) earned "Buy" rating by Suntrust Robinson on Thursday, February 25.

25 October 2017
Cash crunch slowed Puerto Rico's appeal for grid help, CEO says
Besides monetary connections, Whitefish Energy also has direct political connections with some of Trump's cabinet secretaries. But some on Capitol Hill are concerned that Whitefish may have stood out for another reason.

25 October 2017
Brazil vs England: FIFA site goes into meltdown
Look beyond the smile, that's how bad Brazil want this. "They showed a lot of fight and spirit to win the game", Cooper added. But the attacking momentum stayed with Brazil as they went on to score two in quick succession to eventually take the game.

25 October 2017
70 protesting students of QAU arrested
At that time, a heavy contingent of police arrived to control the unrest, firing tear-gas shells to disperse furious students. The university's syndicate has made a three-member committee to review the sentences given to the students.

25 October 2017
Goodyear Tire Rubber (GT) Seeing Increased Volatility in Session
This represents a $0.56 dividend on an annualized basis and a yield of 1.65%. 56 funds opened positions while 158 raised stakes. In related news, insider Jean Claude Kihn sold 7,500 shares of the business's stock in a transaction dated Monday, October 2nd.



Recommended